论文部分内容阅读
目的研究不同剂量副干酪乳杆菌对肝硬化患者肠黏膜屏障的影响。方法选择我院肝硬化失代偿期患者42例,随机分为对照组和副干酪乳杆菌4g、8g、16g组。各组均给予常规对症治疗。在此基础上,除对照组外,其余各组按相应剂量每日口服补充副干酪乳杆菌,连续2周。所有患者均于治疗前后测血清二胺氧化酶、脂多糖。结果给予不同剂量副干酪乳杆菌治疗后,各组患者的二胺氧化酶和脂多糖均有所下降,但只有给予16g副干酪乳杆菌治疗的患者二胺氧化酶和脂多糖与对照组相比差异有统计学意义(t=9.517、10.836,P<0.05),同时该组患者疗前后相比差异亦有统计学意义(t=9.445、7.701,P<0.05)。结论补充16g/d副干酪乳杆菌能帮助改善肝硬化患者肠黏膜屏障功能。
Objective To study the effects of different doses of Lactobacillus paracasei on intestinal mucosal barrier in patients with liver cirrhosis. Methods Forty-two patients with decompensated liver cirrhosis in our hospital were randomly divided into control group and Lactobacillus paracasei 4g, 8g and 16g groups. All groups were given conventional symptomatic treatment. On this basis, in addition to the control group, the remaining groups were orally supplemented with Lactobacillus paracasei at the appropriate dose for 2 consecutive weeks. All patients before and after treatment, serum diamine oxidase, lipopolysaccharide. Results After administration of different doses of Lactobacillus paracasei, diamine oxidase and lipopolysaccharide decreased in all groups, but only diamine oxidase and lipopolysaccharide were significantly decreased in patients treated with 16 g Lactobacillus paracasei compared with the control group The difference was statistically significant (t = 9.517,10.836, P <0.05). At the same time, the difference between the two groups was also statistically significant (t = 9.445,7.701, P <0.05). Conclusion Supplementation of 16 g / d L. paracasei can help improve the intestinal mucosal barrier function in patients with cirrhosis.